Results 211 to 220 of about 118,635,816 (237)
Some of the next articles are maybe not open access.
The role of emicizumab in acquired hemophilia A
Hematology, 2023Abstract Acquired hemophilia is a rare bleeding disorder that predominantly affects older people with potential underlying comorbidities, including cardiovascular and thrombotic risk factors. The current standard therapies with hemostatic agents for acute bleeding and immunosuppression often require inpatient management, are not approved
Jacqueline, Poston +1 more
openaire +2 more sources
Acquired Hemophilia A: A Case Report
Journal of Pharmacy Practice, 2019Hemophilia A, also known as factor VIII deficiency, is a rare disorder caused by an insufficient level of factor VIII, an essential clotting protein. Hemophilia A can be inherited or acquired. Inherited hemophilia A is caused by a mutation to the factor VIII gene on the X chromosome, which is commonly passed down from parents to children.
Mark, Shen +5 more
openaire +2 more sources
Surgery-associated acquired hemophilia A
Annals of Hematology, 2001We present two patients who acquired factor VIII antibodies in the immediate postoperative period. One patient was receiving warfarin that was temporarily discontinued but reintroduced after the procedure. Preoperatively, none gave a history of bleeding, even with past surgeries, and both had normal coagulation tests. Within days of surgery, hemorrhage
G, Theodossiades +4 more
openaire +2 more sources
[Rinsho ketsueki] The Japanese journal of clinical hematology, 2020
Acquired hemophilia A (AHA) is a bleeding disorder due to the autoantibody (inhibitor) production targeting blood coagulation factor VIII. It is characterized by a sudden onset, and it often causes extensive and severe bleeding in soft tissue. The incidence of AHA is 1.48 cases per 1 million individuals per year and is common among postpartum women and
openaire +1 more source
Acquired hemophilia A (AHA) is a bleeding disorder due to the autoantibody (inhibitor) production targeting blood coagulation factor VIII. It is characterized by a sudden onset, and it often causes extensive and severe bleeding in soft tissue. The incidence of AHA is 1.48 cases per 1 million individuals per year and is common among postpartum women and
openaire +1 more source
Rituximab in the Treatment of Acquired Hemophilia
Annals of Pharmacotherapy, 2006Objective: To review published literature evaluating the use of rituximab for treatment of acquired hemophilia. Data Sources: An English-language literature search was conducted using MEDLINE (1966–January 2006).
openaire +2 more sources
Acquired Circulating Anticoagulants in Hemophilia A
New England Journal of Medicine, 1969Abstract Factor VIII inhibitor was found in 16 of 77 patients (21 per cent) with severe hemophilia A. In 12 cases with marked inhibition, this became manifest after as few as 20, but no more than 90, accumulated days of exposure to transfusions, and usually before 10 years of age.
openaire +2 more sources
Adalimumab-associated Acquired Hemophilia in a Patient with Scleritis
Ocular Immunology and Inflammation, 2022Paulina Liberman
exaly
Acquired hemophilia A: a review of recent data and new therapeutic options
Hematology, 2017Giancarlo Maria Liumbruno +2 more
exaly